Form 4: Spyre Therapeutics CEO Sells 45,000 Shares

Spyre Therapeutics CEO Cameron Turtle sold 45,000 shares of common stock for approximately $1.05 million under a pre-arranged 10b5-1 trading plan.

Summary

• Cameron Turtle, Chief Executive Officer and Director of Spyre Therapeutics, Inc. (SYRE), sold a total of 45,000 shares of common stock.
• The sales occurred on November 3, 2025, pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
• The first block of 28,155 shares was sold at a weighted average price of $23.13 per share, with individual transaction prices ranging from $22.51 to $23.50.
• The second block of 16,845 shares was sold at a weighted average price of $23.66 per share, with individual transaction prices ranging from $23.51 to $24.04.
• Following these transactions, Cameron Turtle beneficially owns 701,907 shares of Spyre Therapeutics common stock.
• The remaining beneficial ownership includes 188,743 shares that are subject to monthly vesting over approximately one year, contingent on continued service.

Sentiment

Score: 4

Explanation: The sale of shares by the CEO, even under a 10b5-1 plan, can be perceived as a slightly negative signal by some investors, as it reduces insider ownership. However, the pre-planned nature mitigates immediate concerns about a lack of confidence.

Negatives

• The sale of a significant number of shares by the CEO, even if pre-planned, could be interpreted by some investors as a signal, potentially impacting market sentiment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports an insider stock sale, which is a routine disclosure for public company executives. While individual insider transactions do not inherently reflect broader industry trends, they are closely watched by investors for potential signals regarding management's confidence or personal financial planning.

Stakeholder Impact

• Shareholders may interpret the CEO's sale of shares as a signal, potentially influencing their perception of the company's stock value, although the pre-arranged nature of the sale under a 10b5-1 plan suggests personal financial planning rather than a reaction to company-specific news.

Next Steps

• The remaining 188,743 shares of common stock included in the beneficial ownership will continue to vest in monthly installments over approximately one year, subject to the Reporting Person's continuing service.

Key Dates

Recommendation

While the CEO's sale of shares might be viewed negatively by some, the transaction was executed under a pre-arranged 10b5-1 trading plan, indicating it was a scheduled personal financial event rather than a reactive decision based on new company information. A single Form 4 filing, especially one under a 10b5-1 plan, typically does not provide sufficient information to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and consider this information in the broader context of the company's financial performance, strategic initiatives, and overall market conditions.

Keywords

Spyre Therapeutics, SYRE, Cameron Turtle, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Equity Transaction